DOCSLIB.ORG

Fluoxetine Read All of This Leaflet Carefully Before You Start Taki

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fluoxetine Read All of This Leaflet Carefully Before You Start Taki Package Leaflet: Information for the patient [Product name] Fluoxetine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their sign of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4 What is in this leaflet: 1. What [Product name] are and what they are used for 2. What you need to know before you take [Product name] 3. How to take [Product name] 4. Possible side effects 5. How to store [Product name] 6. Contents of the pack and other information 1. What [Product name] are and what they are used for [Product name] contain the active substance fluoxetine which belongs to a group of medicines called selective serotonin reuptake inhibitor (SSRI) antidepressants. This medicine is used to treat the following conditions: Adults: - Major depressive episodes - Obsessive-compulsive disorder (OCD) - The eating disorder bulimia nervosa: [Product name] are used alongside psychotherapy for the reduction of binge-eating and purging. Children and adolescents aged 8 years and above: - Moderate to severe major depressive disorder, if the depression does not respond to psychological therapy after 4-6 sessions. [Product name] should be offered to a child or young person with moderate to severe major depressive disorder only in combination with psychological therapy. How Fluoxetin Capsule works Everyone has a substance called serotonin in their brain. People who are depressed or have obsessive compulsive disorder or bulimia nervosa have lower levels of serotonin than others. It is not fully understood how Fluoxetine and other SSRIs work but they may help by increasing the level of serotonin in the brain. Treating these conditions is important to help you get better. If it’s not treated, your condition may not go away and may become more serious and more difficult to treat. You may need to be treated for a few weeks or months to ensure that you are free from symptoms. 2. What you need to know before you take [Product name] Do not take [Product name]: 1 • if you are allergic to fluoxetine or any of the other ingredients of this medicine (listed in section 6). If you develop a rash or other allergic reactions (like itching, swollen lips or face or shortness of breath), stop taking the capsules straight away and contact your doctor immediately. • if you are taking other medicines used to treat depression, known as non-selective monoamino oxidase inhibitor or reversible monoamine oxidase inhibitors type A (MAOIs), since serious or even fatal reactions can occur. Examples of MAOIs include nialamide, iproniazide, moclobemide, phenelzine, tranylcypromine, isocarboxazid(used to treat depression) selegiline(used to treat Parkinson’s disease), toloxatone and also linezolid (an antibiotic) and methylthioninium chloride also called methylene blue (used to treat high levels of methaemoglobin in the blood). Treatment with [Product name] should only be started at least 2 weeks after discontinuation of an irreversible MAOI (for instance tranylcypromine). However, treatment with [Product name] can be started the following day after discontinuation of certain reversible MAOIs (for instance moclobemide, linezolid, methylthioninium chloride (methylene blue)). Do not take any MAOIs for at least 5 weeks after you stop taking [Product name]. If [Product name] have been prescribed for a long period and/or at a high dose, a longer interval needs to be considered by your doctor. If you think any of the above points apply to you, do not take the capsules. Talk to your doctor first and follow the advice given. These capsules are available in different strengths from what you may be used to. This is to allow your doctor to more finely control your dose of [Product name] so that you can take the smallest dose needed for you. Please make sure that you know exactly what strength and how many of each capsule you are to take and take care to ensure that you do not take more or less than the prescribed dose. If you are at all unsure please talk to your doctor or pharmacist, you might want to ask them to give you written instructions based on the sizes and marking of the capsule shells. Warnings and precautions Talk to your doctor or pharmacist before taking [Product name] if any of the following applies to you: • epilepsy and fits: if you suffer from or have history of a fit (seizures) or experience an increase in the seizure frequency, contact your doctor immediately; [Product name] might need to be discontinued; • if you are less than 18 years of age • if you suffer from or have history of mania or hypomania (overactive behavior/thoughts or very low moods); if you have a maniac episode, contact your doctor immediately because [Product name] might need to be discontinued; • if you are diabetes (your doctor may need to adjust your dose of insulin or other antidiabetic treatment); • if you have liver problems or heart problems (your doctor may need to adjust your dosage); • if you have low resting heart-rate and/or if you know that you may have salt depletation as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water tablets); • if you suffer from glaucoma (increase pressure in the eye); • if you suffer from any other psychiatric disorders • if you are undergoing treatment with diuretics (water tablets), especially if you are older; • ongoing ECT (electro-convulsive therapy); • have history of bleeding disorders(e.g haemophilia) or appearance of bruises or unusual bleeding; • ongoing treatment with medicines that thin the blood (see “Other medicines and Fluoxetine capsules”); • ongoing treatment with tamoxifen (used to treat breast cancer); • starting to feel restless and cannot sit or stand still (akathisia). Increasing your dose of Fluoxetine capsules may make this worse; 2 • appearance of fever, muscle stiffness or tremor, changes in your mental state like confusion, irritability and extreme agitation; you may suffer from the so-called “serotonin syndrome” or “neuroleptic malignant syndrome”. Although this syndrome occurs rarely it may result in potentially life threatening conditions; contact your doctor immediately, since [Product name] might need to be discontinued. Thoughts of suicide and worsening of your depression or anxiety disorder If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer. You may be more likely to think like this: - If you have previously had thoughts about killing or harming yourself. - If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviours in adults aged less than 25 year with psychiatric conditions who were treated with an antidepressant. If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away. You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour. Children and adolescents aged 8 to 18 years: Patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. [Product name] should only be used in children and adolescents aged 8 to 18 years for the treatment of moderate to severe major depressive episodes (in combination with psychological therapy) and it should not be used to treat other conditions. Additionally, only limited information concerning the long-term safety of [Product name] on growth, puberty, mental, emotional and behavioural development in this age group is available. Despite this, and if you are a patient under 18, your doctor may prescribe [Product name] for moderate to severe major depressive episodes, in combination with psychological therapy, because he/she decides that this is in your best interests. If your doctor has prescribed [Product name] for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking [Product name]. [Product name] should not be used in treatment of children under the age of 8 years. Other medicines and [Product name] Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Do not take [Product name] with: Do not take any irreversible, non-selective MAOIs for at least 5 weeks after you stop taking [Product name]. If [Product name] has been prescribed for a long period and/or at a high dose, a longer interval than 5 weeks may need to be considered by your doctor. • metoprolol when used for heart failure; there is an increased risk of your heart beat becoming too slow. [Product name] may affect the way some other medicines work (interaction), especially the following: certain monoamine oxidase inhibitors (MAOIs, some used to treat depression). Non-selective MAOIs and MAOIs type A must not be used with [Product name] as serious or even fatal 3 reactions (serotonin syndrome) can occur (see section “Do not take [Product name]”).
Load more

Recommended publications
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Cerebral Histamine H1 Receptor Binding Potential Measured With
    Cerebral Histamine H1 Receptor Binding Potential Measured with PET Under a Test Dose of Olopatadine, an Antihistamine, Is Reduced After Repeated Administration of Olopatadine Michio Senda1, Nobuo Kubo2, Kazuhiko Adachi3, Yasuhiko Ikari1,4, Keiichi Matsumoto1, Keiji Shimizu1, and Hideyuki Tominaga1 1Division of Molecular Imaging, Institute of Biomedical Research and Innovation, Kobe, Japan; 2Department of Otorhinolaryngology, Kansai Medical University, Osaka, Japan; 3Department of Mechanical Engineering, Kobe University, Kobe, Japan; and 4Micron, Inc., Kobe, Japan Some antihistamine drugs that are used for rhinitis and pollinosis have a sedative effect as they enter the brain and block the H1 Antihistamines are widely used as a medication for receptor, potentially causing serious accidents. Receptor occu- common allergic disorders such as seasonal pollinosis, pancy has been measured with PET under single-dose adminis- tration in humans to classify antihistamines as more sedating or chronic rhinitis, and urticaria. Some antihistamine drugs as less sedating (or nonsedating). In this study, the effect of re- have a sedative side effect as they enter the brain and block peated administration of olopatadine, an antihistamine, on the histamine H1 receptor, potentially causing traffic accidents cerebral H1 receptor was measured with PET. Methods: A total and other serious events, but the sedative effect is difficult to of 17 young men with rhinitis underwent dynamic brain PET with evaluate because of a large variation in neuropsychological 11 C-doxepin at baseline, under an initial single dose of 5 mg of measures and subjective symptoms. Measurement of cere- olopatadine (acute scan), and under another 5-mg dose after re- 11 peated administration of olopatadine at 10 mg/d for 4 wk (chronic bral histamine H1 receptor occupancy using PET with C- doxepin under a single administration of antihistamines has scan).
    [Show full text]
  • Antihistamine Therapy in Allergic Rhinitis
    CLINICAL REVIEW Antihistamine Therapy in Allergic Rhinitis Paul R. Tarnasky, MD, and Paul P. Van Arsdel, Jr, MD Seattle, Washington Allergic rhinitis is a common disorder that is associated with a high incidence of mor­ bidity and considerable costs. The symptoms of allergic rhinitis are primarily depen­ dent upon the tissue effects of histamine. Antihistamines are the mainstay of therapy for allergic rhinitis. Recently, a second generation of antihistamines has become available. These agents lack the adverse effect of sedation, which is commonly associated with older antihistamines. Current practice of antihistamine therapy in allergic rhinitis often involves random selection among the various agents. Based upon the available clinical trials, chlorpheniramine appears to be the most reasonable initial antihistaminic agent. A nonsedating antihis­ tamine should be used initially if a patient is involved in activities where drowsiness is dangerous. In this comprehensive review of allergic rhinitis and its treatment, the cur­ rent as well as future options in antihistamine pharmacotherapy are emphasized. J Fam Pract 1990; 30:71-80. llergic rhinitis is a common condition afflicting some­ defined by the period of exposure to those agents to which A where between 15 and 30 million people in the United a patient is sensitive. Allergens in seasonal allergic rhinitis States.1-3 The prevalence of disease among adolescents is consist of pollens from nonflowering plants such as trees, estimated to be 20% to 30%. Two thirds of the adult grasses, and weeds. These pollens generally create symp­ allergic rhinitis patients are under 30 years of age.4-6 Con­ toms in early spring, late spring through early summer, sequently, considerable costs are incurred in days lost and fall, respectively.
    [Show full text]
  • Preparing for Your Allergy Testing
    A Patient’s Guide: Preparing for your Allergy Testing Welcome to the Allergy division of the Otolaryngology department at Minor & James Surgical Specialists. We look forward to providing you with the best possible care. Our goal is to see that your entire experience is outstanding from start to finish. Please take a moment to review the following clinic policies. Failure to follow these detailed instructions Allergy Testing Appointment may prolong your appointment or result in rescheduling Appointment Date: for another date. 1. Cancellation Policy: Out of courtesy to our staff and Please arrive at: other patients, please be aware that you will be charged a If you arrive late, your appointment will be $100 cancellation fee if you do not provide at least 48 hour rescheduled. notice should you need to cancel or reschedule your Physician Follow Up Appointment appointment. This fee is not billable to your insurance and will be charged to your account in the office. Exceptions will Dr. John Burgoyne be made on an emergency basis only. 2. Medications: It is very important that you read the Dr. Calvin Knapp attached list of medications that need to be stopped or avoided before testing can be done. If you do take a Dr. Chad Ruffin medication that interferes with allergy testing, please call to discuss or reschedule your testing appointment. Appointment Date: 3. Clothing: Please wear either a comfortable t-shirt or tank Appointment Time: top. Testing is done on both arms, up to the shoulders, both lower and upper. The allergy testing appointment will take roughly 90 minutes.
    [Show full text]
  • A Method to Determine the Ability of Drugs to Diffuse Through the Blood-Brain Barrier ANNA SEELIG*T, RUDOLF GOTTSCHLICHI, and RALF M
    Proc. Natl. Acad. Sci. USA Vol. 91, pp. 68-72, January 1994 Pharmacology A method to determine the ability of drugs to diffuse through the blood-brain barrier ANNA SEELIG*t, RUDOLF GOTTSCHLICHI, AND RALF M. DEVANTf *Biocenter of the University of Basel, Klingelbergstrasse 70, 4056 Basel, Switzerland; and tMedicinal Chemistry Research Laboratories, CNS Department, E. Merck, Frankfurter Strasse 250, 6100 Darmstadt, Germany Communicated by Harden M. McConnell, September 13, 1993 ABSTRACT A method has been devised for predicting the groups, (ii) the number of charged groups and their extent of ability of drugs to cross the blood-brain barrier. The criteria ionization, and (iii) the molecular size. Interestingly, the depend on the amphiphilic properties of a drug as reflected in same three parameters also determine the surface activity Its surface activity. The assessment was made with various and their combined action can be evaluated in a single drugs that either penetrate or do not penetrate the blood-brain experiment by measuring the Gibbs adsorption isotherm. barrier. The surface activity of these drugs was quantified by Here the chromatographically determined lipophilicity their Gibbs adsorption isotherms in terms ofthree parameters: constants are compared with measurements of the surface (i) the onset of surface activity, (ii) the critical micelle concen- activity for a large number of structurally different com- tration, and (iii) the surface area requirement ofthe drug at the pounds known to cross or not to cross the BBB. The air/water interface. A calibration diagram is proposed in predictive value of the surface activity measurements as a which the critical miceUe concentration is plotted against the function of concentration is distinctly higher than that of the concentration required for the onset of surface activity.
    [Show full text]
  • The Anticholinergic Impregnation Scale: Towards The
    Therapie (2017) 72, 427—437 Available online at ScienceDirect www.sciencedirect.com CLINICAL PHARMACOLOGY The anticholinergic impregnation scale: Towards the elaboration of a scale adapted to prescriptions in French psychiatric settings L’échelle d’imprégnation anticholinergique : vers l’élaboration d’une échelle adaptée aux prescriptions en milieu psychiatrique franc¸ais a,b b,c,∗ Jeanne Briet , Hervé Javelot , c d Edwige Heitzmann , Luisa Weiner , c e Catherine Lameira , Philippe D’Athis , e a,b Marie Corneloup , Jean-Louis Vailleau a Pharmacy service, CHS de La Chartreuse, 21000 Dijon, France b PIC network (Psychiatrie Information Communication), EPSM Lille-Métropole, 59487 Armentières, France c Établissement public de santé Alsace Nord, 67170 Brumath, France d Psychiatry II and Inserm unit 1114, university hospital of Strasbourg, 67000 Strasbourg, France e Service of biostatistics and medical informatics, CHU de Dijon, 21000 Dijon, France Received 6 June 2016; accepted 23 December 2016 Available online 17 February 2017 KEYWORDS Summary Anticholinergics; Purpose. — Some drugs have anticholinergic activity and can cause peripheral or central side Anticholinergic drug effects. Several scales exist to evaluate the potential anticholinergic effect of prescribed drugs scale; but: (i) they are validated in the elderly and mainly assess the cognitive side effect of treat- Psychiatry ments; (ii) they do not concern some of the drugs frequently used in clinical psychiatry in France. The aim of our study is to develop a new scale, the anticholinergic impregnation scale (AIS), with drugs used in France and based on an assessment of the drugs used against peripheral anticholinergic adverse effects. ∗ Corresponding author. Clinical pharmacy service, Établissement public de santé Alsace Nord (EPS Alsace Nord), 141 avenue de Strasbourg, 67170 Brumath, France.
    [Show full text]
  • Inhibitory Effect of Olopatadine Hydrochloride on the Sneezing Response Induced by Intranasal Capsaicin Challenge in Guinea Pigs
    Jpn. J. Pharmacol. 86, 258 – 261 (2001) Short Communication Inhibitory Effect of Olopatadine Hydrochloride on the Sneezing Response Induced by Intranasal Capsaicin Challenge in Guinea Pigs Toshihiko Kaise*, Yukino Akamatsu, Kenji Ohmori, Akio Ishii and Akira Karasawa Department of Pharmacology, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan Received December 22, 2000 Accepted April 6, 2001 ABSTRACT—To investigate the possible inhibitory effect of olopatadine hydrochloride (olopatadine), an antiallergic drug, on the tachykinin-mediated nasal responses, we examined the effect of olopatadine on the sneezing and the nasal rubbing responses induced by intranasal capsaicin challenge in guinea pigs. Olopat- adine (10 mg/kg, p.o.) inhibited the sneezing response by 57% without affecting the nasal rubbing one. The antihistamines chlorpheniramine and clemastine did not affect the responses. Morphine caused the inhibition of both responses, which was antagonized by naloxone. These results suggest that olopatadine inhibits the sneezing response by the inhibition of the tachykinin release and not by its antihistaminic action. Keywords: Olopatadine, Tachykinin release, Sneezing response Olopatadine hydrochloride ((Z)-11-(3-dimethylamino- were approved by the Animal Ethical Committee of Kyowa propylidene)-6,11-dihydrobenz[b,e]oxepin-2-acetic acid Hakko Kogyo Co., Ltd. (Shizuoka). monohydrochloride, CAS 140462-76-6, KW-4679) (olopata- Capsaicin (Wako Pure Chemical Industries, Osaka) was dine) is a novel antiallergic drug with an antagonistic action dissolved in 5% ethanol and 5% Tween 80 and then diluted against histamine H1 receptor (1). The previous in vitro with saline to give a solution of 1 mmol/l.
    [Show full text]
  • The Molecular Basis of CYP2D6 Mediated N-Dealkylation
    DMD Fast Forward. Published on August 25, 2008 as DOI: 10.1124/dmd.108.022376 DMD FastThis articleForward. has not Publishedbeen copyedited on and AugustDMD formatted. #22376# 25, The 2008 final version as doi:10.1124/dmd.108.022376 may differ from this version. The Molecular Basis of CYP2D6 mediated N-dealkylation. - Balance between metabolic clearance routes and enzyme inhibition Britta Bonn, Collen M. Masimirembwa, Yasmin Aristei, and Ismael Zamora Downloaded from Discovery DMPK & Bioanalytical Chemisty, AstraZeneca R&D Mölndal, Sweden (B.B., C.M.M.) dmd.aspetjournals.org Department of Chemistry, Medicinal Chemistry, University of Gothenburg, Gothenburg, Sweden. (B.B.) African Institute of Biomedical Science & Technology (AiBST), Harare, Zimbabwe. (C.M.M) at ASPET Journals on September 24, 2021 Department of Chemistry, Laboratory for Chemometrics and Chemoinformatics, University of Perugia, Perugia, Italy. (Y.A.) Lead Molecular Design, S.L., San Cugat del Vallés, Spain. (I.Z.) Institution Municipal d´Investigació Medica (IMIM), Universitat Pompeu Fabra, Barcelona, Spain. (I.Z) Copyright 2008 by the American Society for Pharmacology and Experimental Therapeutics. 1 DMD Fast Forward. Published on August 25, 2008 as DOI: 10.1124/dmd.108.022376 This article has not been copyedited andDMD formatted. #22376# The final version may differ from this version. RUNNING TITLE PAGE Molecular Basis of CYP2D6 mediated N-dealkylation Corresponding author: Britta Bonn. Discovery DMPK & Bioanalytical Chemistry, AstraZeneca R&D Mölndal, SE-431 81 Mölndal,
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Randomised Double Masked Trial Comparing the Efficacy And
    336 Br J Ophthalmol: first published as 10.1136/bjo.2003.021907 on 20 February 2004. Downloaded from SCIENTIFIC REPORT Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides pteronyssinus B Mortemousque, A Jacquet, C Richard, F Depont, J Colin, N Moore ............................................................................................................................... Br J Ophthalmol 2004;88:336–340. doi: 10.1136/bjo.2003.021907 seasonal conjunctivitis. Mequitazine was clearly superior to Aim: A double masked randomised trial comparing 0.05% placebo in preventing redness and itching,8 significantly mequitazine eye drops with 0.05% levocabastine and superior to 2% disodium cromoglycate9 and 0.1% dexametha- placebo was carried out in otherwise heatlhy volunteers sone,10 and was similar to levocabastine in reducing allergic to house dust mites (Dermatophagoides pteronyssi- hyperaemia and itching.11 nus). However, it seemed interesting to test mequitazine on a Method: Double masked, randomised, single centre study, model of perennial conjunctivitis. For this purpose, a double comparing three parallel treatment groups. 60 healthy adults masked randomised trial comparing mequitazine eye drops with a confirmed history of allergic conjunctivitis to house with levocabastine and placebo was carried out in subjects dust mites for at least 2 years were included and completed responsive to Dermatophagoides pteronyssinus allergen. The aim the trial. Conjunctival provocation tests (CPT) were done at of the study was to show the non-inferiority of topical 0.05% screening, at visit 2 (V2) (1 week later), and at visit 3 (V3) mequitazine compared to 0.05% levocabastine eye drops and (2 weeks after V2).
    [Show full text]
  • Antihistamines in Atopic Dermatitis Therapy
    Khamaganova I, et al., J Allergy Disord Ther 2015, 2: 003 DOI: 10.24966/ADT-749X/100003 HSOA Journal of Allergy Disorders and Therapy Review article cases we can see vicious circle formed by pruritus pathophysiology Antihistamines in Atopic and neurologic or psychic disorders on the other hand. Clinically, antihistamines, i.e., histamine H1-receptor blockers, Dermatitis Therapy are commonly used to treat all types of itching resulting from renal and liver diseases, as well as from serious skin diseases such as 1,2 1 Nikolay Potekaev , Irina Khamaganova * and Irina Atopic Dermatitis (AD) [7]. Antihistaminic drugs prescribed in AD 1 Vorontsova may support the therapy of the itching skin disease. However, there 1Department of Skin Diseases & Cosmetology, Pirogov Russian National are no controlled studies which show the efficacy of antihistaminic Medical University, Moscow, Russia drugs on the skin condition in AD. 2 Moscow Department of Health, Moscow, Russia Rossbach K et al., demonstrated that histamine induces a calcium increase in a subset of skin-specific sensory neurons via activation of the H1R and H4R as well as inhibition of the H3R. The decreased threshold in response to H3R antagonism activated H1R and H4R Summary on sensory neurons, which in turn resulted in the excitation of The review of antihistamine therapy in atopic dermatitis is presented. histamine-sensitive afferents and therefore elicited the sensation of Traditionally, antihistamines are being used to treat itching which itch [8]. is the crucial sign of atopic dermatitis with a major impact on We can find contradictory hypothesis about the feasibility of health-related quality of life.
    [Show full text]
  • 209089Orig1s000 209090Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209089Orig1s000 209090Orig1s000 CLINICAL REVIEW(S) CLINICAL REVIEW Application Type NDA (Rx to OTC switch) Application Number(s) 209-089 Xyzal Allergy 24 HR tablets 209-090 Xyzal Allergy 24 HR solution Priority or Standard Standard Submit Date(s) March 18, 2016 Received Date(s) March 31, 2016 PDUFA Goal Date January 31, 2017 Division / Office DPARP/ODE 2/OND Reviewer Name(s) Xu Wang, M.D., Ph.D. Review Completion Date December 9, 2016 Established Name Levocetirizine dihydrochloride Rx Trade Name Xyzal tablets/solution OTC Trade Name Xyzal Allergy 24HR tablets/solution Therapeutic Class Antihistamine Applicant UCB Inc. Formulation(s) tablets/solution Dosing Regimen ≥12 years: One tablet (5 mg) daily/10 mL solution (5 mg) daily; 1 6 – 11 years: /2 tablet (2.5 mg) daily/5 mL solution (2.5 mg) daily; 2 – 5 years: 2.5 mL solution (1.25 mg) daily Indication(s) Temporarily relieve these symptoms due to hay fever or other upper respiratory allergies: • running nose, • sneezing, • itchy, watering eyes, • itching of nose or throat Intended Population(s) Tablets: ≥6 years of age Solution: ≥2 years of age Template Version: March 6, 2009 Reference ID: 4025819 Clinical Review Xu Wang, M.D., Ph.D. NDA 209-089/NDA 209-090 Rx to OTC switch Xyzal Allergy 24HR (levocetirizine dihydrochloride) tablets/solution Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT .........................................4 1.1 Recommendation on Regulatory Action ............................................................. 4 1.2 Risk Benefit Assessment .................................................................................... 4 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 4 2.1 Product Information ............................................................................................ 4 2.2 Currently Available Treatments for Proposed Indications..................................
    [Show full text]